J.Lewis Research Inc

Salt Lake City, Utah 84121

1 studies enrolling now · 14 studies all time

What they study most

Abscess, Acute Treatment of Migraine, Bacterial Skin Diseases, Diabetes Mellitus, Type 2, Infectious Skin Diseases, Influenza, Low Back Pain, Meningococcal Infections, Migraine, Migraine Disorders, Obesity, PAR

Studies at this site

• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Recruiting now
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both — Completed
• A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults — Completed
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine — Completed
• Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age — Completed
• Long Term Safety Study of Tanezumab in Chronic Low Back Pain — Stopped early
• Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza — Stopped early
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children — Completed
• A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise — Completed
• A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). — Completed
• Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections — Completed
• Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o. — Status unconfirmed